Supernus stock to delist from Nasdaq after merger closes

Supernus Pharmaceuticals disclosed in an 8-K filing dated November 2, 2026 that it completed a merger and moved to take its common stock off Nasdaq. In connection with the consummation of the Merger on November 2, 2026, Supernus notified Nasdaq of the completion of the Merger and requested that Nasdaq suspend trading of the Supernus Common Stock, effective prior to the opening of trading on November 2, 2026, and file with the SEC a Notification of Removal from Listing and/or Registration on Form 25 to effect the delisting of the Supernus Common Stock from Nasdaq and the deregistration of the Supernus Common Stock under Section 12(b) of the Securities Exchange Act of 1934.¹

The company also outlined further steps to wind down its public reporting status. Following the effectiveness of the Form 25, Supernus intends to file with the SEC a certification on Form 15 requesting deregistration of the Supernus Common Stock under Section 12(g) of the Exchange Act and the suspension of its reporting obligations under Sections 13 and 15(d) of the Exchange Act.¹

As a direct result of the transaction, the Supernus Common Stock will no longer be listed on any national securities exchange.¹

The filing was signed on behalf of the company by Timothy C. Dec, Senior Vice President and Chief Financial Officer, on November 2, 2026.¹ The 8-K does not identify the merger counterparty or describe transaction terms beyond the delisting and deregistration steps.